Iratumumab Withdrawn Phase 2 Trials for Lymphoma, Large-Cell Treatment

IndicationsStatusPurposePhase
WithdrawnTreatment2
clinicaltrials.gov IdentifierTitleDrugs
NCT00298467MDX-060 in Patients With Relapsed or Refractory Classic Systemic or Primary Cutaneous Anaplastic Large Cell Lymphoma